PMID- 22052195
OWN - NLM
STAT- MEDLINE
DCOM- 20120530
LR  - 20120208
IS  - 1573-7209 (Electronic)
IS  - 0969-6970 (Linking)
VI  - 15
IP  - 1
DP  - 2012 Mar
TI  - The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances 
      angiogenesis but does not reduce tumor growth rate.
PG  - 165-9
LID - 10.1007/s10456-011-9239-8 [doi]
AB  - There has been a long controversy as to whether interleukin-17 (IL17) has an 
      impact on tumor growth. In order to assess whether IL17 may affect tumor growth, 
      it would be convenient to achieve high levels of this pro-inflammatory cytokine 
      at the tumor neo-vasculature, since IL17 is known to promote angiogenesis. Here, 
      we have generated and tested in vivo a fusion protein, consisting of the F8 
      antibody (specific to the alternatively spliced EDA domain of fibronectin, a 
      marker of angiogenesis) and of murine IL17 (mIL17). The resulting immunocytokine 
      (termed F8-mIL17) was shown to selectively localize at the tumor neo-vasculature 
      and to vigorously promote tumor angiogenesis, without however reducing or 
      enhancing tumor growth rate both in immunocompetent and in immunodeficient mice.
FAU - Pasche, Nadine
AU  - Pasche N
AD  - Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical 
      Sciences, ETH Zurich, Wolfgang-Pauli-Strasse 10, 8093 Zurich, Switzerland.
FAU - Frey, Katharina
AU  - Frey K
FAU - Neri, Dario
AU  - Neri D
LA  - eng
PT  - Journal Article
DEP - 20111104
PL  - Germany
TA  - Angiogenesis
JT  - Angiogenesis
JID - 9814575
RN  - 0 (Antibodies)
RN  - 0 (Interleukin-17)
RN  - 0 (Recombinant Fusion Proteins)
SB  - IM
MH  - Animals
MH  - Antibodies/immunology
MH  - Cell Line
MH  - Cell Proliferation/drug effects
MH  - Cloning, Molecular
MH  - Drug Delivery Systems/*methods
MH  - Interleukin-17/pharmacology/*therapeutic use
MH  - Mice
MH  - Neoplasms/*blood supply/*drug therapy/pathology
MH  - Neovascularization, Pathologic/*drug therapy/pathology
MH  - Recombinant Fusion Proteins/pharmacology/therapeutic use
MH  - Subcutaneous Tissue/drug effects/pathology
EDAT- 2011/11/05 06:00
MHDA- 2012/05/31 06:00
CRDT- 2011/11/05 06:00
PHST- 2011/05/31 00:00 [received]
PHST- 2011/10/20 00:00 [accepted]
PHST- 2011/11/05 06:00 [entrez]
PHST- 2011/11/05 06:00 [pubmed]
PHST- 2012/05/31 06:00 [medline]
AID - 10.1007/s10456-011-9239-8 [doi]
PST - ppublish
SO  - Angiogenesis. 2012 Mar;15(1):165-9. doi: 10.1007/s10456-011-9239-8. Epub 2011 Nov 
      4.